Psoriatic arthritis and spondyloarthritis assessment and management updatePhilip Mease
Swedish Medical Center, Seattle WA, USA
Curr Opin Rheumatol 25:287-96. 2013
....
Update on treatment of psoriatic arthritisPhilip Mease
Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA
Bull NYU Hosp Jt Dis 70:167-71. 2012
..Anti-TNF therapies remain the gold standard of effectiveness. New therapeutic options are potentially emerging including ustekinumab, abatacept, several IL-17 inhibitors, apremilast, JAK inhibitors, and possibly IL-6 inhibitors...
- The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial
Philip J Mease
Seattle Rheumatology Associates, 1101 Madison Street, Suite 1000, Seattle, WA 98104, USA
J Rheumatol 36:398-409. 2009
..To evaluate the safety and efficacy of milnacipran, a dual norepinephrine and serotonin reuptake inhibitor, in the treatment of fibromyalgia (FM)...
- Estimation of minimum clinically important difference for pain in fibromyalgia
Philip J Mease
Swedish Medical Center and University of Washington School of Medicine, Seattle, USA
Arthritis Care Res (Hoboken) 63:821-6. 2011
..To estimate the minimum clinically important difference (MCID) for several pain measures obtained from the Brief Pain Inventory (BPI) for patients with fibromyalgia...
Fibromyalgia syndrome module at OMERACT 9: domain constructPhilip Mease
Seattle Rheumatology Associates and Division of Rheumatology Research, Swedish Medical Center, Seattle, WA 98104, USA
J Rheumatol 36:2318-29. 2009
..In conclusion, a multidimensional symptom core set is proposed for evaluation of FM in clinical trials. Research on improved measures of single domains and composite measures is ongoing...
- Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy?
Philip J Mease
Seattle Rheumatology Associates, Swedish Medical Center, Seattle, WA 98104, USA
Curr Pain Headache Rep 12:399-405. 2008
..Trials are currently being developed to assess the potential additive or synergistic effects of combined central pharmacotherapy and to assess the safety and tolerability of this approach...
- Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept
Philip J Mease
Seattle Rheumatology Associates, Seattle, Washington 98104, USA
J Rheumatol 33:712-21. 2006
..Clinical and radiographic responses were evaluated in patients with psoriatic arthritis (PsA) treated for up to 2 years with etanercept...
- Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis
Philip J Mease
Seattle Rheumatology Associates and Swedish Medical Center, 1101 Madison Street, Seattle, WA 98104, USA
J Rheumatol 37:1221-7. 2010
..To evaluate the effects of etanercept treatment on patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA)...
- Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update
Philip J Mease
Division of Rheumatology Research, Swedish Medical Center, University of Washington, Seattle, Washington, USA
J Rheumatol 38:1487-95. 2011
..Final results of this work will be published in a separate report pending completion of analyses...
- Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study
Philip J Mease
Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Wahington 98104, USA
J Rheumatol 37:692-703. 2010
....
- Single-joint outcome measures: preliminary validation of patient-reported outcomes and physical examination
Alison E Heald
Targeted Genetics Corporation, Seattle, Washington, USA
J Rheumatol 37:1042-8. 2010
..To assess the validity, responsiveness, and reliability of single-joint outcome measures for determining target joint (TJ) response in patients with inflammatory arthritis...
- Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial
Philip J Mease
Seattle Rheumatology Associates, Swedish Medical Center, Seattle, WA 98104, USA
J Rheumatol 37:917-27. 2010
..To assess the efficacy and safety of 1 versus 2 courses of rituximab over 48 weeks in patients with rheumatoid arthritis (RA)...
- Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial
Philip J Mease
Seattle Rheumatology Associates, Seattle, WA 98104, USA
J Rheumatol 35:20-30. 2008
....
- A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia
Philip J Mease
Seattle Rheumatology Associates, Seattle, Washington 98104, USA
J Rheumatol 35:502-14. 2008
..To evaluate the efficacy and safety of pregabalin for symptomatic relief of pain associated with fibromyalgia (FM) and for management of FM...
- Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia
Philip J Mease
Seattle Rheumatology Associates, Seattle, WA, USA
Semin Arthritis Rheum 39:454-64. 2010
..To assess the long-term safety, tolerability, and efficacy of duloxetine in patients with fibromyalgia...
- Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction
Philip J Mease
Swedish Medical Center and University of Washington, Seattle, WA 98104, USA
J Rheumatol 38:2461-5. 2011
..To evaluate changes in function as measured by Health Assessment Questionnaire Disability Index (HAQ-DI) and the meaningfulness of the changes, in importance and satisfaction, in patients with psoriatic arthritis (PsA)...
- Pharmacotherapy of fibromyalgia
Philip J Mease
Rheumatology Research, Swedish Medical Center, Seattle, WA, USA
Best Pract Res Clin Rheumatol 25:285-97. 2011
..Current therapies neither completely treat FM symptoms nor benefit all patients; thus, further research on new therapies with different mechanisms and side-effect profiles is needed...
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial
Philip J Mease
Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Washington 98104, USA
Arthritis Rheum 52:3279-89. 2005
..Adalimumab, a fully human, anti-tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA)...
- Improving the routine management of rheumatoid arthritis: the value of tight control
Philip J Mease
Seattle Rheumatology Associates, Seattle, Washington 98104, USA
J Rheumatol 37:1570-8. 2010
..A case study clearly demonstrates the benefits of the tight control approach in routine clinical practice...
- Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study
Philip J Mease
Seattle Rheumatology Associates, Division of Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA
J Am Acad Dermatol 60:402-11. 2009
..A single course of alefacept intramuscularly in combination with methotrexate (MTX) was effective in treating both psoriasis and psoriatic arthritis (PsA)...
- Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: practical applications for rheumatology healthcare providers
Nicole Furfaro
Seattle Rheumatology Associates, Seattle, Washington 98104, USA
J Am Acad Nurse Pract 23:479-92. 2011
....
- Fibromyalgia syndrome
Philip J Mease
Swedish Medical Center, The University of Washington School of Medicine, Seattle, WA, USA
J Rheumatol 32:2270-7. 2005
..A prioritized list of domains of FM to be investigated was thus developed, key issues and controversies in the field were debated, and consensus on a research agenda on outcome measure development was reached...
- Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study
Philip J Mease
Swedish Medical Center, Seattle, Washington, USA
Arthritis Rheum 54:1638-45. 2006
..To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic arthritis (PsA)...
- Psoriatic arthritis: pharmacotherapy update
Philip J Mease
Swedish Medical Center, Division of Rheumatology Research, Seattle Rheumatology Associates, University of Washington, 1101 Madison Street, Suite 1000, Seattle, WA 98104, USA
Curr Rheumatol Rep 12:272-80. 2010
....
- Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression
Philip J Mease
Seattle Rheumatology Associates, Seattle, Washington 98104, USA
Arthritis Rheum 50:2264-72. 2004
..In this study, we further evaluated the safety, efficacy, and effect on radiographic progression of etanercept in patients with PsA...
- Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials
Philip J Mease
Seattle Rheumatology Associates, Seattle, WA 98104, USA pmease nwlink com
Dermatology 220:1-7. 2010
..Psoriatic arthritis often affects patients with psoriasis...
- Prologue: 2010 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
Philip J Mease
Swedish Medical Center and University of Washington, Seattle, Washington 98104, USA
J Rheumatol 39:391-3. 2012
..Introductions to the discussions at the GRAPPA 2010 meeting are included in this prologue...
- Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
Philip J Mease
University of Washington, Seattle, WA 98104, USA
J Rheumatol 38:522-5. 2011
..Other topics for discussion at the GRAPPA meeting included presentations on genetic associations with PsA and on comorbidities in patients with PsA. Current and future research projects also were outlined...
- Psoriatic arthritis assessment and treatment update
Philip J Mease
Seattle Rheumatology Associates, Seattle, Washington, USA
Curr Opin Rheumatol 21:348-55. 2009
..To review the current state of knowledge about assessment and management of psoriatic arthritis (PsA)...
- Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis
Philip J Mease
Seattle Rheumatology Associates, Seattle, WA 98104, USA
Expert Opin Biol Ther 5:1491-504. 2005
..In addition, structural changes were inhibited, and statistically and clinically significant improvements in measures of disability and quality of life were observed. Adalimumab was generally safe and well tolerated...
- Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors
Philip J Mease
Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Washington, USA
Am J Med 122:S44-55. 2009
..Pharmacologic agents that specifically target serotonin and norepinephrine reuptake may prove to be valuable tools in the treatment of fibromyalgia...
- Pharmacotherapy of fibromyalgia
Philip J Mease
Seattle Rheumatology Associates, Swedish Medical Center, Seattle, WA 98104
Rheum Dis Clin North Am 35:359-72. 2009
....
- Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective
Philip J Mease
Seattle Rheumatology Associates, Seattle, Washington 98104, USA
J Am Acad Dermatol 54:685-704. 2006
....
- Spondyloarthritis update: new insights regarding classifcation, pathophysiology, and management
Philip J Mease
University of Washington School of Medicine, Seattle, Washington, USA
Bull NYU Hosp Jt Dis 66:203-9. 2008
..International treatment recommendations have been or are being developed based on the evidence base from clinical trials...
- Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions
Philip J Mease
Seattle Rheumatology Associates, Rheumatology Clinical Research, Swedish Medical Center, University of Washington School of Medicine, Seattle, WA, USA
Semin Arthritis Rheum 38:320-35. 2009
..To identify and describe measures that can be used to assess the impact of psoriatic arthritis (PsA) on patient functioning and health-related quality of life (HRQOL)...
- B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application
Philip J Mease
Seattle Rheumatology Associates, Seattle, Washington 98104, USA
J Rheumatol 35:1245-55. 2008
..In this review we explore the rationale behind B cell-targeted therapy, highlight the results of clinical trials with rituximab in RA and other autoimmune diseases, and describe other emerging therapies directed at B cells...
- Assessment tools in psoriatic arthritis
Philip J Mease
Seattle Rheumatology Associates, Seattle, Washington 98104, USA
J Rheumatol 35:1426-30. 2008
..We present a review of those discussions...
- Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment
Philip J Mease
Seattle Rheumatology Associates, Seattle, WA 98104, USA
J Rheumatol 38:1546-51. 2011
..Evidence is presented for the efficacy of centrally acting analgesics for OA pain (opioids, antiepileptics, tricyclic antidepressants, and serotonin/norepinephrine receptor inhibitors)...
- Current treatment of psoriatic arthritis
Philip J Mease
Seattle Rheumatology Associates, Division of Clinical Research, Swedish Hospital Medical Center, University of Washington School of Medicine, Seattle, WA, USA
Rheum Dis Clin North Am 29:495-511. 2003
....
- Psoriatic arthritis therapy advances
Philip J Mease
Seattle Rheumatology Associates, Swedish Medical Center, Rheumatology Research Division, and University of Washington School of Medicine Seattle, Washington 98104, USA
Curr Opin Rheumatol 17:426-32. 2005
..This paper will review the data published in 2004 on the treatment of psoriatic arthritis, which arthritis affects 6 to 39% of all patients with psoriasis...
- Psoriatic arthritis: update on pathophysiology, assessment and management
Philip J Mease
Seattle Rheumatology Associates, 1101 Madison St Ste 1000, Seattle, WA 98104, USA
Ann Rheum Dis 70:i77-84. 2011
..Although there is considerable overlap with RA, there are some differences in pathophysiology and approach to assessment and management that are important to consider. This paper reviews these subjects, with an emphasis on recent data...
- Recent advances in the management of psoriatic arthritis
Philip J Mease
Seattle Rheumatology Associates, Seattle, Washington 98104, USA
Curr Opin Rheumatol 16:366-70. 2004
..Newer trials in psoriatic arthritis therapy demonstrate ongoing ability to control disease symptoms and signs and the progression of the disease significantly...
- Nursing considerations for infusion therapy in rheumatoid arthritis versus malignancy
Nicole Furfaro
Seattle Rheumatology Associates, Seattle, Washington 98104, USA
J Infus Nurs 31:350-60. 2008
..This article focuses on the specific pathophysiology of the RA disease state and patient characteristics that may affect infusion therapy, illustrated by a case study...
- Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety
Philip J Mease
Seattle Rheumatology Associates, Seattle, WA 98104, USA
Rheumatology (Oxford) 50:261-70. 2011
..CZP was generally well tolerated when used either as monotherapy or added to MTX; most adverse events were mild or moderate. Taken together, the results of these trials suggest that CZP is an effective new option for the treatment of RA...
- Biomarkers of Radiographic Progression in Psoriatic Arthritis: A Report from the GRAPPA 2011 Annual Meeting
Oliver Fitzgerald
From the Department of Rheumatology, St Vincent s University Hospital, Dublin, Ireland Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA and Rheumatology Research, Swedish Medical Center, and Department of Rheumatology, University of Washington, Seattle, Washington, USA
J Rheumatol 39:2189-92. 2012
....
- On Defining Musculoskeletal Inflammation: A Report from the GRAPPA 2011 Annual Meeting
Amit Garg
From the Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA University of Toronto, Toronto Western Research Institute, Toronto, Ontario, Canada and Swedish Medical Center and University of Washington, Seattle, Washington, USA
J Rheumatol 39:2214-5. 2012
..In breakout group discussions, GRAPPA members discussed the difficulties in recognizing overlapping or mimicking features that may result in underdiagnosing or misdiagnosing PsA...
- Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy
Philip J Mease
Seattle Rheumatology Associates, Seattle, Washington, USA
J Rheumatol 32:616-21. 2005
..CONCLUSION: Prasterone treatment prevented BMD loss and significantly increased BMD at both the lumbar spine and total hip in female patients with SLE receiving exogenous glucocorticoids...
- Disease-modifying antirheumatic drug therapy for spondyloarthropathies: advances in treatment
Philip J Mease
Seattle Rheumatology Associates, Seattle, Washington 98104, USA
Curr Opin Rheumatol 15:205-12. 2003
..This article reviews recent progress in disease-modifying therapy for spondyloarthropathy, including new biologic response modifiers, such as the tumor necrosis factor-alpha inhibitors etanercept and infliximab...
